We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

272 hedge funds and large institutions have $4.2B invested in Mirum Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 91 increasing their positions, 77 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

429% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 14

49% more capital invested

Capital invested by funds: $2.82B → $4.2B (+$1.38B)

27% more funds holding

Funds holding: 214272 (+58)

18% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 77

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

2.32% more ownership

Funds ownership: 111.83%114.15% (+2.3%)

8% less call options, than puts

Call options by funds: $7.16M | Put options by funds: $7.75M

Holders
272
Holders Change
+58
Holders Change %
+27.1%
% of All Funds
3.57%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.13%
New
74
Increased
91
Reduced
77
Closed
14
Calls
$7.16M
Puts
$7.75M
Net Calls
-$587K
Net Calls Change
+$2.92M
Name Holding Trade Value Shares
Change
Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$498M
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$367M -$15.2M -238,691 -5%
BlackRock
3
BlackRock
New York
$264M +$1.61M +25,343 +0.7%
Vanguard Group
4
Vanguard Group
Pennsylvania
$187M -$1.24M -19,500 -0.8%
EAM
5
Eventide Asset Management
Massachusetts
$185M -$7.31M -114,922 -4%
BI
6
BVF Inc
California
$110M -$80.5M -1,266,043 -46%
State Street
7
State Street
Massachusetts
$98.7M -$1.83M -28,724 -2%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$94.1M -$8.51M -133,927 -9%
NHAS
9
Novo Holdings A/S
Denmark
$92.7M -$15M -236,027 -16%
TCM
10
Tang Capital Management
California
$90.6M
Citadel Advisors
11
Citadel Advisors
Florida
$76.3M -$23.3M -365,808 -26%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$74.1M -$1.25M -19,594 -2%
ClearBridge Investments
13
ClearBridge Investments
New York
$73.6M -$1.51M -23,724 -2%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$67.7M +$23.4M +368,552 +66%
PCH
15
Polar Capital Holdings
United Kingdom
$60.2M -$9.82M -154,448 -16%
Wellington Management Group
16
Wellington Management Group
Massachusetts
$58M +$42.7M +672,118 +567%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$58M +$33.8M +531,809 +205%
RSCM
18
Rock Springs Capital Management
Maryland
$55.8M -$3.63M -57,080 -7%
Morgan Stanley
19
Morgan Stanley
New York
$49.1M +$6.6M +103,823 +18%
Lord, Abbett & Co
20
Lord, Abbett & Co
New Jersey
$48.5M -$6.94M -109,206 -14%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$46.9M +$36.9M +580,777 +977%
Arrowstreet Capital
22
Arrowstreet Capital
Massachusetts
$44.9M +$34.1M +536,674 +709%
N
23
Nuveen
North Carolina
$44.1M +$726K +11,413 +2%
Franklin Resources
24
Franklin Resources
California
$44.1M +$479K +7,541 +1%
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$44.1M +$7.6M +119,609 +25%

MIRM Hedge Fund Activity: Q3 2025 in Review

272 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2025, worth a combined $4.2B — up 49% from $2.82B a quarter earlier.

Buyers outnumbered sellers: 74 funds opened new MIRM positions and 14 closed out — a net gain of 60 holders — while 91 added to existing stakes and 77 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $42.7M. The largest seller was BVF Inc, cutting an estimated $80.5M.

  • 272 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2025, up from 214 in Q2 2025.
  • Funds reported $4.2B of Mirum Pharmaceuticals stock for Q3 2025, up 49% quarter-over-quarter.
  • 74 funds opened new Mirum Pharmaceuticals positions in Q3 2025 and 14 closed out, a net change of +60 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $42.7M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2025 was BVF Inc, an estimated $80.5M sold.

Based on aggregated 13F filings for Q3 2025.